Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Nov 9, 2010


David Ledbetter has left his position at Emory University to become chief scientific officer and executive vice president of Geisinger Health System.

Before joining Danville, Pa.-based Geisinger, Ledbetter was director of the division of medical genetics at Emory University School of Medicine in Atlanta. Prior to Emory, Ledbetter was the founding chair of the department of human genetics at the University of Chicago, where he served along Glenn Steele, who was then dean of the school of biological sciences and is now president and CEO of Geisinger.

In his new role, Ledbetter said that he is interested in "getting clinical genomic data into medical records in a useful way, anticipating the day when routine care produces genomic data." He added that the move to Geisinger will not interfere with his leadership of the International Standards for Cytogenomic Arrays consortium.

Christa Lese Martin, senior laboratory director of the Emory Genetics Laboratory, said that the university is now seeking a "physician scientist with an active research program to build a strong clinical program" to fill Ledbetter's former position.

Both Ledbetter and Martin spoke to BioArray News during the American Society of Human Genetics annual conference, held in Washington, DC, last week.

Molecular Response last week appointed Thomas Broudy to be its chief scientific officer.

Prior to joining San Diego-based MRL, Broudy served as director at AltheaDx, working closely with that firm's business development and R&D teams. Before that, he spent six years at Affymetrix, where he "led efforts to define requirements, content and applications" for the company’s DMET drug metabolism array, according to MRL.

Broudy holds a PhD in infectious disease from Rockefeller University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.